Immunovant (NASDAQ:IMVT) Director Atul Pande Sells 6,000 Shares

Immunovant, Inc. (NASDAQ:IMVT) Director Atul Pande sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $32.00, for a total value of $192,000.00. Following the completion of the transaction, the director owned 116,731 shares of the company’s stock, valued at approximately $3,735,392. This represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunovant Stock Up 35.3%

Shares of IMVT traded up $9.27 during trading on Wednesday, reaching $35.56. The company’s stock had a trading volume of 19,557,655 shares, compared to its average volume of 1,413,486. The company has a fifty day moving average of $26.48 and a two-hundred day moving average of $25.78. Immunovant, Inc. has a twelve month low of $13.79 and a twelve month high of $36.29. The company has a market cap of $7.24 billion, a price-to-earnings ratio of -13.22 and a beta of 0.70.

Immunovant (NASDAQ:IMVT) last announced its earnings results on Wednesday, May 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.13). During the same quarter in the prior year, the business earned ($0.64) earnings per share. As a group, equities analysts forecast that Immunovant, Inc. will post -2.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunovant

Several large investors have recently added to or reduced their stakes in IMVT. RTW Investments LP acquired a new stake in Immunovant in the fourth quarter worth $80,781,000. Morgan Stanley increased its position in Immunovant by 147.4% in the fourth quarter. Morgan Stanley now owns 4,846,385 shares of the company’s stock worth $123,195,000 after buying an additional 2,887,359 shares during the period. Jennison Associates LLC increased its position in Immunovant by 356.4% in the first quarter. Jennison Associates LLC now owns 3,196,705 shares of the company’s stock worth $79,406,000 after buying an additional 2,496,241 shares during the period. ADAR1 Capital Management LLC increased its position in Immunovant by 319.0% in the third quarter. ADAR1 Capital Management LLC now owns 2,241,753 shares of the company’s stock worth $36,137,000 after buying an additional 1,706,687 shares during the period. Finally, Logos Global Management LP increased its position in Immunovant by 400.0% in the fourth quarter. Logos Global Management LP now owns 1,375,000 shares of the company’s stock worth $34,952,000 after buying an additional 1,100,000 shares during the period. 47.08% of the stock is owned by institutional investors and hedge funds.

Immunovant News Summary

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Immunovant reported promising Week 16 data from its difficult-to-treat rheumatoid arthritis study, with strong response rates that investors are viewing as evidence the lead program could have meaningful clinical potential. QuiverQuant article
• Positive Sentiment: The company said its cutaneous lupus proof-of-concept study is fully enrolled, with topline results expected in the second half of 2026, keeping multiple catalysts ahead for IMVT-1402. GlobeNewswire article
• Neutral Sentiment: Immunovant reported quarterly results showing a wider-than-expected loss, with EPS of -$0.73 versus the -$0.60 consensus, but the earnings miss appears to have taken a back seat to the clinical update. Earnings report
• Neutral Sentiment: Management also highlighted a strong cash position of about $902 million at March 31, 2026, suggesting enough runway to support development plans through a potential commercial launch. GlobeNewswire article
• Negative Sentiment: Despite the stock’s rally, the company still faces execution risk because IMVT-1402 remains in clinical development and future results will need to confirm today’s optimistic early readout.

Wall Street Analysts Forecast Growth

IMVT has been the topic of several research reports. Guggenheim upped their price target on Immunovant from $41.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunovant in a research report on Wednesday, April 8th. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Immunovant in a research note on Tuesday, February 10th. Sanford C. Bernstein initiated coverage on shares of Immunovant in a research note on Friday, March 20th. They set a “market perform” rating and a $28.00 price objective on the stock. Finally, The Goldman Sachs Group lifted their target price on Immunovant from $29.00 to $32.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Immunovant presently has an average rating of “Hold” and an average target price of $32.44.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.